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Introduction
Cystic Fibrosis (CF) is a multi-system life-limiting genetic 
condition in which the most common cause of death is respira-
tory failure. Daily use of inhaled mucolytic and antibiotic medi-
cations are effective to prevent pulmonary exacerbations and 
preserve lung function1,2. Low adherence to CF medications 
is associated with poorer health outcomes3, yet real-world 
adherence to inhaled medications is only 35–50%4,5. 
Another problem is the potential for diagnostic uncertainties 
– in a study where the objectively measured adherence was 36%, 
people with CF reported median adherence of 80% whilst clini-
cians estimated adherence rate of 55–60%5. This disparity makes 
it challenging for healthcare professionals to make informed 
clinical decisions. The ‘invisibility’ of adherence in routine 
care can result in consultations characterised by the ‘lamp post 
syndrome’6, whereby there is a tendency for clinicians to use 
readily available information which can be misleading. In 
other words, clinicians ended up seeking information “where 
the light is” rather than to use all relevant data sources. Since 
neither patient self-report nor clinician estimation provides 
an accurate indication of medication adherence, adherence 
will be invisible in those centres without systems that make 
objectively measured adherence visible. This lack of adher-
ence data is critical for diagnosis and assessment. Indeed, the 
approach in a patient with deteriorating clinical status and low 
adherence (where treatment failure is due to non-use of 
existing treatments) is very different to the approach in a 
patient with deteriorating clinical status and high adherence 
(where existing treatments have failed, and treatment escalation 
must be considered).
Furthermore, enabling self-monitoring using objective feed-
back is associated with increases in target health behaviours7 
and has been identified as a facilitator in nebuliser adherence8. 
Access to, and feedback from, accurate adherence data could 
facilitate more effective self-monitoring and self-care for people 
with CF.
Despite evidence pointing to the importance of objectively meas-
ured adherence data in routine CF care, it remains unclear how 
frequently clinicians readily have access to objective adher-
ence data in their day-to-day practice and whether such access 
is desired by clinicians. We therefore conducted an online 
survey among UK CF centres to establish the perceived impor-
tance of routinely available adherence data, and the extent to 
which this data is currently used in routine care.
Methods
Centre directors from all 29 UK adult CF centres were invited 
by email on 12 March 2019 to participate in a short online ques-
tionnaire about their views and practices in using adherence 
data in their day-to-day management of people with CF. Where 
available, contact details were sought through the CF regis-
try; in the absence of this, email addresses were ascertained 
through hospital websites.
Centre directors were encouraged to discuss the questions 
with their clinical colleagues before responding. Centres that 
did not respond after two weeks were sent two reminders, at 
two week intervals. All responses were collected within two 
weeks of the final reminder. 
The participant information sheet detailed that responses to the 
survey would be used for research purposes. The information 
sheet was embedded within the invitation email. Consent to par-
ticipate was implied through completion of the questionnaire. 
The questionnaire was designed with Qualtrics© 2019 software 
(version March 2019, Provo, Utah) and consisted of five-
items with a mixture of Likert scale, percentage estimate and 
free-text responses (see Extended data). Respondent Internet 
Protocol (IP) addresses were captured and used to check for 
duplicate responses. No duplicate responses were captured.
Responses to Likert scale questions (Q1, Q4) were coded 
1–5 (1= Very important, 5= Not important) and medians and 
inter-quartile ranges summarised. For responses to questions 
requesting a percentage estimate (Q2, Q3), means and standard 
deviations were calculated. Free-text responses (Q5) were 
summarised by extracting key themes.
The study received approval from the School of Health and 
Related Research (ScHARR) Research Ethics Committee, Uni-
versity of Sheffield (ref: 024042). The survey was hosted on 
Qualtrics (survey tool approved by the University of Sheffield 
Corporate Information and Computing Services). The University 
of Sheffield was the data controller and all survey data exported 
for analysis was stored on an access restricted folder on 
the University shared file store.
Results
A total of eight adult UK CF centres (28%) provided data 
from sites across England, Northern Ireland and Wales. 
Summaries by questionnaire item are summarised in Table 1. 
An average of 87% of patients using inhaled therapies were 
estimated not to have up to date medicines possession ratio 
or pharmacy refill data available during a typical outpa-
tient clinic. This included four centres that said 100% of their 
patients would not have this information available. Across five 
centres, an average of 83% of patients were estimated not to 
have I-neb® data readily available at the point of consulta-
tion. It was stated by two sites that I-nebs were not used at 
their centre and it is important to recognise that at the time the 
study, the only routinely available devices to collect objective 
adherence data were Inebs®.
In contrast to low availability of objective adherence data, 
all centres considered having up-to-date, objective adher-
ence data for inhaled therapies at the point of diagnosis to be at 
least moderately important; 57% considered this to be impor-
tant and a further 29% considered this to be very important. 
When asked if they thought that a system able to automatically 
collect and provide objective, up-to-date adherence data within 
a consultation would be important, all responding centres said 
that this would be important to have in their centre and 50% of 
respondents felt this would be very important.
A total of seven free-text responses were received for ques-
tion five regarding the key features for a system to routinely 
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collect objective adherence data. Multiple respondents stated 
that “ease of use” would be important, as well as quick and reli-
able data access. Centres also stated that it would be important 
for data to be available for both patients and staff to facilitate 
discussions on adherence.
Conclusion
Adherence is important for accurate diagnosis, treatment 
planning and self-management in people with CF3,6,8. We have 
demonstrated that whilst centres providing care to people with 
CF perceive objective adherence data to be important, com-
prehensive provision of these data is not a feature of current CF 
clinical practice. A small percentage of people with CF have 
objective measures of adherence available for consultations 
(between 13–17% depending on the use of medication 
possession ratio or I-neb®). This is despite an overall con-
sensus that access to objective adherence data is important 
for making accurate diagnoses. If a system could produce 
up-to-date, routinely collected objective adherence data for 
use in consultations, all centres felt this would be an important 
asset.
The results of this study demonstrate that in the responding 
centres clinicians felt that objectively measured adherence at 
the point of consultation would be useful but was rarely avail-
able. A limitation of the current study is that with only 8 out of 
29 UK adult centres responding, it is uncertain whether objec-
tive adherence data is considered important across the whole of 
the UK. Nevertheless, it is notable that within the centres that 
did respond, there was a consensus that objective adherence 
data was important and no centres that considered objective 
adherence data to be unimportant.
Ethical approval
Ethical approval for the collection and analysis of data 
was obtained from School of Health and Related Research 




ORDA: Findings from a national questionnaire survey of UK 
CF centres on availability and desirability of routinely available 
adherence data, https://doi.org/10.15131/shef.data.10059251.v19.
This project contains the following underlying data:
-    CSV file exhibiting the responses to the questionnaire 
for the eight centres
Extended data
ORDA: Findings from a national questionnaire survey of UK 
CF centres on availability and desirability of routinely available 
adherence data, https://doi.org/10.15131/shef.data.10059251.v19.
This project contains the following extended data:
-   Questionnaire sent to the CF centers
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
Table 1. Questionnaire responses summarised by item (excluding free-text responses to question 5).
Question n Median (IQR) n responses (%)
Q1: A clinical vignette to ascertain whether clinicians desire objective adherence 
data at the point of consultation 
7 2 (1 – 2) Very important: 2 (29%) 
Important: 4 (57%) 
Moderately important: 1 (14%)
Q4: The perceived importance of a system which provides objective adherence 
data at the point of consultation 
How important is it to have such a system in your centre?
6 1.5 (1- 2) Very important: 3 (50%) 
Important: 3 (50%)
1= “Very important”, 2= “Important”, 3= “Moderately important”, 4= “Slightly important”, 5= “Not important”
n Mean (SD)
Q2: Proportion of adults whereby pharmacy refill data is readily available at the 
point of consultation
6 13% (31%)
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